Novartis
NEWS
There’s clearly a need for new antibiotics to fight infections. If so, why are so many companies in the space abandoning it or going out of business?
In addition to the three preclinical assets from Novartis, Gilead has recently entered into deals to develop therapies for HIV, RA and NASH.
Novartis saw a strong boost in sales during the second quarter, driven by Cosentyx and Entresto, as well as a 9% growth in oncology sales, the company announced this morning.
It was a typically busy week for clinical trials, with announcements in a wide variety of indications. Here’s a look.
The companies indicate they hope to continue data analysis to better understand the disease and will present anything relevant at a future scientific meeting.
As the largest center for biotech startups in the U.S., the Boston/Cambridge, Massachusetts area often acts as a marker for the entire industry. Here’s a look at the Massachusetts M&A deals so far.
Preclinical data has shown that the combination of a KRAS G12C inhibitor with a SHP2 inhibitor results in increased anti-tumor activity based on their complementary mechanisms of action.
As fireworks illuminate the night skies across the United States this weekend in celebration of Independence Day, BioSpace takes a look at some of the highlights of the pharma industry from the first half of 2019 and earlier that provides millions of patients with the independence of health.
Novartis announced that it has completed its acquisition of Xiidra® 5%, the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease.
JOBS
IN THE PRESS